Quick Answer
Bone Biologics Corp reported Operating Income Loss of -$3.23 million for the year ending 2025.
- Bone Biologics Corp showed an increase of +23.3% in Operating Income Loss from 2024 to 2025.
- This data is from Bone Biologics Corp's annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$923.4 thousand | Q2 2015: -$510.6 thousand | Q3 2015: -$2.97 million | Q1 2016: -$9.10 million | Q2 2016: -$4.34 million | Q3 2016: -$3.86 million | Q1 2017: -$2.16 million | Q2 2017: $1.97 million | Q3 2017: -$1.13 million | Q1 2018: -$1.10 million | Q2 2018: -$860.2 thousand | Q3 2018: $404.8 thousand | Q1 2019: -$1.19 million | Q2 2019: -$679.3 thousand | Q3 2019: -$301.3 thousand | Q1 2020: -$340.1 thousand | Q2 2020: -$132.7 thousand | Q3 2020: -$145.8 thousand | Q1 2021: -$180.9 thousand | Q2 2021: -$231.9 thousand | Q3 2021: -$229.8 thousand | Q1 2022: -$689.5 thousand | Q2 2022: -$469.3 thousand | Q3 2022: -$1.22 million | Q1 2023: -$3.15 million | Q2 2023: -$3.04 million | Q3 2023: -$2.08 million | Q1 2024: -$903.5 thousand | Q2 2024: -$809.7 thousand | Q3 2024: -$951.0 thousand | Q1 2025: -$1.04 million | Q2 2025: -$748.1 thousand | Q3 2025: -$715.3 thousand.
- Over the full 13 years of available data (2013 to 2025), Bone Biologics Corp's Operating Income Loss has declined by 381.4%.
- Historical annual values: Fiscal year 2025: -$3.23 million | Fiscal year 2024: -$4.22 million | Fiscal year 2023: -$9.43 million | Fiscal year 2022: -$3.67 million | Fiscal year 2021: -$1.10 million | Fiscal year 2020: -$825.0 thousand | Fiscal year 2019: -$2.45 million | Fiscal year 2018: -$2.79 million | Fiscal year 2017: -$2.63 million | Fiscal year 2016: -$20.41 million | Fiscal year 2015: -$12.00 million | Fiscal year 2014: -$3.01 million | Fiscal year 2013: -$672.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: